Join our daily newsletter At The Bell to receive exclusive market insights
- SUDA Pharmaceuticals (ASX:SUD) has appointed biochemistry expert Dr Michael Baker as its new CEO
- Dr Michael has experience in drug development, portfolio management, product testing, and research
- With a PhD in Biochemistry from La Trobe University, he has helped write over 15 research articles and been cited over 1000 times
- SUDA creates medical mouth-sprays designed to treat epilepsy, insomnia, and even cancer
- SUDA’s shares are up 4.29 per cent today currently worth 7.3 cents each
SUDA Pharmaceuticals has appointed biochemistry expert Dr Michael Baker as its new CEO.
Dr Michael will start his new role at the company on January 2, 2020, and with him comes years of experiences both in business and medicine.
As an Investment Associate at Bioscience Managers, Dr Michael has experience in sourcing and landing deals from various events and institutes. He also has experience in portfolio management and the development and testing of different products.
In medicine, Dr Michael has helped write over 15 research articles and accumulated more than 1000 citations.
He spent roughly three years as a Project Manager at biotech company Hexima where he helped guide a peptide drug product through discovery to clinical trials. This involved leading a team of research scientists.
Dr Michael has a PhD in Biochemistry from La Trobe University in Melbourne, as well as a Master of Business Administration from Melbourne Business School.
On top of the new role of CEO, Dr Michael will also be replacing Paul Hopper as Executive Chairman of SUDA, who will become a Non-Executive Chairman.
Paul spoke highly of the calibre of the new company CEO.
“Michael’s expertise across commercialisation of technologies, scientific research and financial investments is a core asset, which is important for SUDA as it repositions itself,” Paul said.
“With refreshed company management going forward we are striving to rebuild company value and shareholder confidence,” he said.
SUDA is focussed on developing drugs in the form of an oral spray. The company says less than 25 per cent of conventional tablet and pill medication is actually absorbed by the body, and so SUDA’s focus is the efficacy of drug delivery.
The company has developed mouth-spray products to treat epilepsy, insomnia, motion sickness, and even cancer.
SUDA’s shares are up 4.29 per cent after today’s news, currently worth 7.3 cents each and trading in a $10.38 million market cap.
